Abstract 1385 Identifying δ- and κ-opioid protomer selective compounds utilizing robust computational workflows for future δ-κ-opioid heteromer receptor targeting

While μ-opioid agonists remain the therapeutic gold standard for pain management, abuse liability, tolerance, and the risk of life-threatening side effects like respiratory depression severely limit their clinical utility. Amongst the search for viable alternatives are novel agonists targeting the δ- or κ-opioid receptors (DOR and KOR, respectively). Unfortunately, the current landscape of drugs that singly target DOR or KOR protomers has shown limited efficacy and undesirable side effects (e.g., dysphoria).